Efficacy and Safety of Shenqi Fuzheng Injection Combined with Transarterial Chemoembolization in the Treatment of Patients with Middle and Advanced Liver Cancer
Objective:To analyze the efficacy and safety of Shenqi Fuzheng Injection combined with transarterial chemoembolization(TACE)in the treatment of patients with middle and advanced liver cancer.Method:A total of 98 patients with middle and advanced liver cancer who received treatment in Guangzhou First People's Hospital from January 2021 to December 2022 were selected as the study objects,and they were divided into study group and control group by random number table method,with 49 cases in each group.The control group was treated with TACE only,while the study group was treated with intravenous Shenqi Fuzheng Injection on the basis of TACE.The clinical effective rate,liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST)],immunological indexes(CD3+,CD4+,CD8+ and CD4+/CD8+),incidence of adverse reactions and quality of life of the two groups were compared.Result:The total clinical effective rate of the study group was 79.59%,which was higher than 63.27%of the control group,the difference was statistically significant(P<0.05).At 2 weeks after surgery,ALT and AST in both groups were lower than those 1 d before surgery,and the above indexes in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).At 2 weeks after surgery,the levels of CD3+,CD4+ and CD4+/CD8+ in the study group were higher than those 1 d before surgery and control group,while CD8+ levels were lower than those 1 d before treatment and control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the study group was 30.61%,which was lower than 57.14%in the control group,and the difference was statistically significant(P<0.05).The improvement rate of quality of life in the study group was 91.84%,which was higher than 65.31%in the control group,and the difference was statistically significant(P<0.05).Conclusion:Shenqi Fuzheng Injection combined with TACE can improve the clinical effective rate of patients with middle and advanced liver cancer,protect the liver function of patients,reduce the adverse reactions after TACE,and improve the immunological level and clinical quality of life.
万方数据
维普
